ICH M4Q(R2) 质量指南:人用药品注册通用技术文档 (CTD):质量
VIP免费
i
INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL
REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE
ICH HARMONISED GUIDELINE
THE COMMON TECHNICAL DOCUMENT FOR
THE REGISTRATION OF PHARMACEUTICALS
FOR HUMAN USE: QUALITY
M4Q(R2)
Draft version
Endorsed on 14 May 2025
Currently under public consultation
At Step 2 of the ICH Process, a consensus draft text or guideline, agreed by the
appropriate ICH Expert Working Group, is transmitted by the ICH Assembly to the
regulatory authorities of the ICH regions for internal and external consultation,
according to national or regional procedures.
M4Q(R2)
Document History
Code
History
Date
M4Q(R2)
Endorsement by the Members of the ICH
Assembly under Step 2 and release for public
consultation.
14 May 2025
Legal notice: This document is protected by copyright and may, with the exception of the ICH
logo, be used, reproduced, incorporated into other works, adapted, modified, translated or
distributed under a public license provided that ICH's copyright in the document is
acknowledged at all times. In case of any adaption, modification or translation of the document,
reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes
were made to or based on the original document. Any impression that the adaption,
modification or translation of the original document is endorsed or sponsored by the ICH must
be avoided.
The document is provided "as is" without warranty of any kind. In no event shall the ICH or the
authors of the original document be liable for any claim, damages or other liability arising from
the use of the document.
The above-mentioned permissions do not apply to content supplied by third parties. Therefore,
for documents where the copyright vests in a third party, permission for reproduction must be
obtained from this copyright holder.
iii
ICH HARMONISED GUIDELINE
THE COMMON TECHNICAL DOCUMENT FOR THE
REGISTRATION OF PHARMACEUTICALS FOR
HUMAN USE: QUALITY
M4Q(R2)
ICH Consensus Guideline
TABLE OF CONTENTS
SCOPE AND ORGANISATION ...................................................................................................... 1
MODULE 2. COMMON TECHNICAL DOCUMENT SUMMARIES ....................................... 4
2.3. Quality Overview ..........................................................................................................................4
2.3.1 General Information....................................................................................................................4
2.3.2 Overall Development and Overall Control Strategy.................................................................. 4
2.3.2.1 Quality Target Product Profile ...................................................................................... 4
2.3.2.2 Overall Development Strategy ...................................................................................... 5
2.3.2.3 Overall Control Strategy Representation ...................................................................... 5
2.3.3 Core Quality Information........................................................................................................... 5
2.3.3.DS Drug Substances.........................................................................................................5
2.3.3.SI Substance Intermediates, if Applicable ........................................................................ 8
2.3.3.SM Starting/Source Materials .......................................................................................... 9
2.3.3.RM Raw Materials ............................................................................................................9
2.3.3.EX Excipients................................................................................................................. 10
2.3.3.RS Reference Standards and/or Materials ......................................................................11
2.3.3.DP Drug Products .......................................................................................................... 12
2.3.3.PI Product Intermediates, if Applicable ......................................................................... 14
2.3.3.MD Medical Devices, if Applicable ................................................................................14
2.3.3.PM Packaged Medicinal Products for multiconstituent products, if Applicable........... 16
2.3.3.PH Pharmaceutical Product after transformation, if Applicable.................................. 17
2.3.3.AP Analytical Procedures ...............................................................................................17
2.3.3.FA Facilities....................................................................................................................18
2.3.4 Development Summary and Justification .................................................................................18
2.3.4.IN Integrated Development and Justifications ...............................................................18
2.3.4.DS Drug Substances.......................................................................................................20
摘要:
展开>>
收起<<
iINTERNATIONALCOUNCILFORHARMONISATIONOFTECHNICALREQUIREMENTSFORPHARMACEUTICALSFORHUMANUSEICHHARMONISEDGUIDELINETHECOMMONTECHNICALDOCUMENTFORTHEREGISTRATIONOFPHARMACEUTICALSFORHUMANUSE:QUALITYM4Q(R2)DraftversionEndorsedon14May2025CurrentlyunderpublicconsultationAtStep2oftheICHProcess,aconsensusdraftt...
声明:如果您的权利被侵害,请联系我们的进行举报。
相关推荐
-
IATF16949-2016中英文对照版
2024-04-30 905 -
IATF16949-2016管理评审报告VIP免费
2024-06-12 167 -
新版APQP第三版和CP控制计划第一版 最新的变化点汇总VIP免费
2025-08-04 104 -
IATF16949标准条款VIP免费
2025-11-12 80 -
IATF16949 汽车认证方案——获得并保持IATF认可的规则(第六版)
2025-11-16 468 -
IATF 16949认可解释VIP免费
2025-11-16 56 -
IATF16949:2016中英文版本1012VIP免费
2025-11-17 69 -
IATF16949乌龟图VIP免费
2025-11-24 40 -
IATF16949全套体系资料汇编(质量手册+程序文件+记录表格)
2025-11-28 310 -
IATF16949体系文件——潜在供应商评估表VIP免费
2025-11-28 83
作者:冒牌货
分类:法规规范
价格:80质量币
属性:59 页
大小:569.26KB
格式:PDF
时间:2025-12-22

